In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Plasma omentin significantly predicts cardiovascular events independently from the presence and extent of angiographically determined baseline coronary artery disease

Session Poster session 2

Speaker Christoph Saely

Event : ESC Congress 2014

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Poster Session

Authors : CH Saely (Triesen,LI), A Leiherer (Feldkirch,AT), A Muendlein (Feldkirch,AT), A Vonbank (Fedlkirch,AT), P Rein (Fedlkirch,AT), K Geiger (Feldkirch,AT), H Drexel (Philadelphia,US)

C.H. Saely1 , A. Leiherer2 , A. Muendlein2 , A. Vonbank3 , P. Rein3 , K. Geiger2 , H. Drexel4 , 1Private University of the Principality of Liechtenstein - Triesen - Liechtenstein , 2VIVIT Institute - Feldkirch - Austria , 3Academic Teaching Hospital, Department of Internal Medicine - Fedlkirch - Austria , 4Drexel University College of Medicine - Philadelphia - United States of America ,

European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 222

Purpose: No prospective data on the power of the new adipocytokine omentin to predict cardiovascular events are available. We therefore aimed at investigating i) the association of plasma omentin with cardiometabolic risk markers, ii) its association with angiographically determined coronary atherosclerosis, and iii) the power of plasma omentin to predict cardiovascular events.

Methods: We measured plasma omentin in a series of 295 patients undergoing coronary angiography for the evaluation of established or suspected stable CAD; presence of baseline CAD was defined as the presence of any lumen irregularities at angiography; the extent of baseline CAD was defined as the number of significant coronary stenoses ≥50%; prospectively cardiovascular events were recorded over a mean follow-up period of 3.5 years.

Results: During this period, 17.6% of our patients suffered cardiovascular events, corresponding to an annual event rate of 5.3%. Plasma omentin did not differ significantly between patients with and subjects without significant CAD (p=0.783), but prospectively omentin significantly predicted cardiovascular events after adjustment for age, gender, BMI, diabetes, hypertension, LDL cholesterol, HDL cholesterol and smoking with a standardized adjusted hazard ratio (HR) of 1.41 [95% CI 1.16-1.72], p<0.001, as well as after additional adjustment for the presence and extent of CAD at the baseline angiography (HR 1.52 [95%CI 1.23-1.86], p<0.001).

Conclusions: From this first prospective evaluation of the cardiovascular risk associated with plasma omentin we conclude that elevated omentin is a strong predictor of cardiovascular events independently from the presence of baseline CAD.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are